Cancer-Binding Adjuvant Polymers for Localized TLR/STING Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunotherapies for cancer, such as immune checkpoint inhibitors and Toll-like receptor agonists, face challenges including limited therapeutic windows due to systemic inflammation and immune reactions, and the use of tumor-targeting proteins can induce immune responses, limiting dose frequency.
Innovation Solution
Development of polymers that target unpaired cysteines on tumor cell surfaces using TLR or STING agonists, avoiding tumor-targeting proteins, to enhance immune activation selectively in the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Toll-like receptor agonists are used to trigger innate immune system activation, then antigen-specific T cell response is potentiated, but non-specific immune activation produces excessive systemic inflammation leading to chronic disease
Solution Approach 1:
The patent applies local quality by making the immune activation effect localized to the tumor microenvironment rather than systemic. The adjuvant is conjugated to a tumor-targeting protein that directs it specifically to tumor cells, ensuring that immune activation occurs only where needed (in the tumor) and not systemically, thereby resolving the contradiction between effective immune response and avoidance of systemic inflammation
Solution Approach 2:
The patent uses a tumor-targeting protein as an intermediary carrier that delivers the adjuvant specifically to tumor cells. This intermediary enables selective delivery of the immune-activating agent to the target site, allowing potent immune response activation in the tumor microenvironment while preventing non-specific systemic immune activation and inflammation
2Reliability
If tumor-targeting proteins are used to target adjuvants to the tumor microenvironment, then cancer targeting is achieved, but immunogenicity of the platform limits the number of doses that can be used due to induction of immune reactions
Solution Approach 1:
The patent applies parameter changes by modifying the chemical properties of the targeting moiety from a protein-based platform to a small molecule or peptide with different immunogenic characteristics. This parameter change maintains tumor-targeting capability while reducing immunogenicity, thereby enabling repeated dosing without inducing harmful immune reactions against the carrier itself
3Object-affected harmful factors
If a fully synthetic tumor cell-surface binding material is developed without immunogenic polypeptides, then systemic inflammation is reduced, but the ability to specifically target tumor cells must be maintained through alternative mechanisms
Solution Approach 1:
The patent applies copying by using small molecule or peptide-based structures that mimic the tumor-targeting function of protein platforms without possessing the same immunogenic properties. These synthetic analogs copy the essential binding capability to tumor cell surfaces while eliminating the harmful immunogenic response, thereby achieving both reduced systemic inflammation and maintained tumor cell specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymers effectively accumulate TLR or STING agonists in tumors, reducing systemic inflammation and enhancing antigen-specific T cell responses, thereby slowing tumor growth and improving survival in cancer models.
Implementation Method 1
B comprises a pyridyl disulfide moiety or a maleimide moiety
Implementation Method 2
A comprises a group that binds to an Antigen Presenting Cell (APC) mannose receptor
Data Source
AI summary
Disclosed herein are compositions comprising immune-activating agents that bind the tumor cell surface in the absence of a tumor-targeting protein component. Described herein are methods and compositions for targeting a TLR or STING agonist to tumor cells and/or cells in the tumor microenvironment. It is hypothesized that the metabolic stress of tumor growth also produces an excess of unpaired cysteines on cell surface proteins relative to the rest of the body. Therefore, this chemistry can be used with compounds that would preferentially target unpaired cysteines on cell surface proteins.